Results 231 to 240 of about 138,238 (309)

Clinical application of a modified platelet desialylation test for mechanistic characterization of platelet transfusion refractoriness

Transfusion, EarlyView.
Abstract Background Platelet transfusion refractoriness (PTR) is a major challenge in transfusion medicine and may result from both immune and non‐immune mechanisms. Although alloantibodies are well‐established contributors, Fc‐independent pathways such as platelet desialylation have emerged as alternative mechanisms of clearance.
Karen Ziza, Thamy Silva, Mateus Domentino, Marina Conrado, João Oliveira, Elyse Moritz, Akemi Chiba, Vanderson Rocha, Alfredo Mendrone‐Junior, José Bordin, Langhi Dante, Carla Dinardo   +11 more
wiley   +1 more source

Second Primary Subglottic Laryngeal Carcinoma After Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone (CHOP) Chemotherapy for Non-Hodgkin Lymphoma. [PDF]

Cureus
Sanal C, Jaiswal I, Biswal P, Kharbuli L.   +3 more
europepmc   +1 more source

Chemical Exposures, DNA Methylation and Whole Blood DNA Damage in Pet Golden Retrievers

Veterinary and Comparative Oncology, EarlyView.
ABSTRACT Canine multicentric lymphoma (CL) is a common and typically fatal cancer among dogs. Although certain breeds have a higher incidence of CL, its environmental risk factors remain uncertain. Exposures to herbicides and volatile organic compounds (VOCs) associate with non‐Hodgkin lymphoma in people.
Ashleigh N. Tindle, Mark E. Berres, Lauren Baker, Zhuonan Wu, Brenna Swafford, Julia Labadie, Lauren A. Trepanier   +6 more
wiley   +1 more source

Burden of Middle-Aged and Elderly Patients With Non-Hodgkin Lymphoma From 1990 to 2021: A Systematic Analysis Based on the Global Burden of Disease 2021. [PDF]

Cancer Med
Chen Y, Jiang Y, Xu Y, Ma Y, Yao W, Cao Q, Zhang X, Peng L, Tang Y, Cheng Y, Ren R, Chen X, Lang H.   +12 more
europepmc   +1 more source

Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u27s lymphoma [PDF]

, 2018
Bartlett, N. L, et al,
core   +1 more source

Changes in 1‐year relative survival of patients with cancer during the COVID‐19 pandemic in Denmark, Finland, Iceland, Norway, and Sweden: A population‐based cohort study

International Journal of Cancer, Volume 158, Issue 12, Page 3121-3131, 15 June 2026.
What's new? In the first year of the COVID‐19 pandemic, cancer reporting in the Nordic countries declined, presumably owing to delays in cancer diagnosis. How the pandemic impacted cancer survival in these countries, however, remains unclear. Using data from Nordic cancer registries that together include more than 27 million people, the authors of the ...
Fernando Gonzalez Yli‐Mäyry, Tomas Tanskanen, Karri Seppä, Anna L. V. Johansson, Charlotte Wessel Skovlund, Lina Steinrud Mørch, Søren Friis, Simon Mathis Kønig, Tom Børge Johannesen, Tor Åge Myklebust, Sasha Pejicic, David Pettersson, Eva María Guðmundsdóttir, Sirpa Heinävaara, Nea Malila, Joonas Miettinen, Johan Ahlgren, Giske Ursin, Janne Pitkäniemi   +18 more
wiley   +1 more source

Distribution and clinical significance of peripheral blood lymphocyte PD-1 and PD-L1 in non-Hodgkin lymphoma: a retrospective study in Chinese patients. [PDF]

Front Oncol
Liu L, Wang L, Wang W, Wang Y, Wang Y, Xu N, Li N, Liu H.   +7 more
europepmc   +1 more source

Lymphoma, multiple myeloma and leukaemia incidence in regions of Belarus most heavily contaminated by the Chernobyl accident

International Journal of Cancer, Volume 158, Issue 12, Page 3161-3172, 15 June 2026.
What's new? The 1986 Chernobyl accident led to widespread radioactive contamination across parts of Europe, with elevated childhood leukaemia rates observed in heavily affected areas of Ukraine. Data on long‐term haematological and other non‐thyroid cancer risk in the general population in heavily contaminated regions, however, remain limited.
Ljubica Zupunski, Alesia Yaumenenka, Ilya Veyalkin, Victor Minenko, Pavel Moiseyev, Joachim Schüz, Tatiana Kukhta, Sergey Trofimik, Richard Harbron, Vladimir Drozdovitch, Evgenia Ostroumova   +10 more
wiley   +1 more source

A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma. [PDF]

Clin Cancer Res
Strati P, Feng L, Tyshevich A, Shavronskaya D, Alesse J, English N, Sheehan E, Syzrantsev N, Nesmelov A, Zhuang TZ, Chihara D, Westin JR, Ahmed S, Fayad LE, Henderson J, Dent K, McChesney E, Neelapu SS, Flowers CR.   +18 more
europepmc   +1 more source

High Soluble Tumor Necrosis Factor Receptor 2 in Serum Is Associated With Inferior Overall Survival Across Major Lymphoma Subtypes

American Journal of Hematology, Volume 101, Issue 6, Page 1388-1397, June 2026.
ABSTRACT Soluble tumor necrosis factor receptor 2 (sTNFR2) is a member of the TNF superfamily whose normal bodily distribution is largely limited to low level expression on lymphoid cells. It has emerged as an important inducible receptor that activates a signaling pathway for cancer growth.
Arushi Khurana, Hikaru Hayashi, Bethany Thach, Zhi Zhang Yang, Brianna J. Negaard, James R. Cerhan, Anne J. Novak, Brian K. Link, Thomas M. Habermann, Andrew L. Feldman, Sameer A. Parikh, Susan L. Slager, Stephen M. Ansell, Matthew J. Maurer, Denise L. Faustman   +14 more
wiley   +1 more source